Canada : Bausch Health Announces U.S. Launch of DUOBRII Lotion 0.01%/0.045% for Plaque Psoriasis in Adults.
"The DUOBRII formulation brings together two well-known ingredients in a unique lotion vehicle with low concentrations of halobetasol propionate and tazarotene, into a single, first-of-its-kind topical treatment. We are proud to provide plaque psoriasis patients this important new option, which offers strong efficacy and an extended duration of use in an advanced once daily lotion that can be dosed to clearance." When used separately to treat plaque psoriasis, the duration of use of halobetasol propionate is limited by FDA labeling constraints to two to four weeks duration and the use of tazarotene can be limited due to tolerability concerns. By combining halobetasol propionate and tazarotene in a patented once-daily moisturizing lotion, the DUOBRII formulation ensures uniform distribution, allowing for simultaneous contact with the skin surface.
In a year-long safety study, patients used DUOBRII for up to 24 weeks of continuous use and up to 52 weeks of as-needed use. Unlike other topical products that either contain steroids or are steroids on their own, DUOBRII is not restricted to eight weeks or less of use. The approved labeling for DUOBRII does not include a duration limitation? it can be dosed to clearance as long as local skin reactions do not occur, and treatment should be discontinued once clearance is achieved. "Combination therapy is an important tool in the treatment of plaque psoriasis and, with the launch of DUOBRII, I am excited to offer patients a new option that provides the known benefits of a potent topical corticosteroid and a topical retinoid, with synergistic efficacy," said Lawrence J. Green, M.D., associate clinical professor of Dermatology, George Washington University School of Medicine, Washington, D.C. "Due to its tolerability profile, I believe many psoriasis patients will be able to benefit from the longer duration of use possible with DUOBRII." DUOBRII Lotion is priced at $825 for a supply of a 100-gram tube, which is more than 50 percent lower than other branded topical combination products. Additionally, through the company's access program, most eligible, commercially insured patients will have a copay as little as $25.
DUOBRII Comprehensive Clinical Data A Phase 2 study demonstrated DUOBRII Lotion was consistently more effective than its individual agents and vehicle in achieving treatment success (defined as at least a two-grade improvement from baseline in an Investigator Global Assessment (IGA) score, and 'clear' or 'almost clear' skin) and reducing psoriasis signs of erythema, plaque elevation, and scaling at the target lesion. In addition, a post-hoc analysis of the data, in which the vehicle effect was removed, showed that the efficacy of DUOBRII was superior to the aggregated results of the individual agents, supporting the synergy of the two ingredients when combined in one lotion formulation. The safety and efficacy of the once daily use of DUOBRII for the treatment of plaque psoriasis were assessed in two Phase 3 prospective, multi-center, randomized, double-blind clinical trials in subjects 18 years and older with moderate to severe plaque psoriasis. Studies 1 and 2, which enrolled a total of 418 patients, showed DUOBRII was consistently more effective than vehicle in achieving treatment success (primary endpoint at eight weeks), demonstrating statistically significant superiority by week four (in Study 1) and week two (in Study 2). At week eight, 36 percent (Study 1) and 45 percent (Study 2) had achieved the primary efficacy outcome, compared to seven percent and 13 percent on vehicle (both p
[c] 2019 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 1, 2019|
|Previous Article:||Bahrain : gulf air features united nations videos on its inflight entertainment system.|
|Next Article:||Germany : New generation of the GLC and GLC Coup: Starting signal for the series production at the Mercedes-Benz Bremen plant.|